National Intersectoral MHPSS Emergency Preparedness And Response Plan: In The Context Of The Risk Of

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:

Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.

The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:

Registration link for PFA Trainings: https://forms.gle/NzJe3mEYynuCKemr6
Key messages and videos: Link
4Ws platform: https://mhis.nmhp-lb.com/#/account/login

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	180,421 L.L
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	218,344 L.L
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	203,405 L.L
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	179,272 L.L
J02AC01	STABILANOL	G	Fluconazole - 2mg/ml	2mg/ml	Injectable solution	1,291,789 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	133,856 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	163,184 L.L
A03BB01	SCOBUREN	G	Butylscopolamine bromide - 20mg/ml	20mg/ml	Injectable solution	370,901 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	176,974 L.L
A03BB01	SCOPINAL	G	Butylscopolamine bromide - 20mg/ml	20mg/ml	Injectable solution	178,731 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	161,805 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	161,314 L.L
B05BB01	SOLUFLEX LACTATED RINGER'S INJECTION, USP	G	Sodium lactate - 3.1g/l, Calcium chloride, 2H2O - 0.2g/l, Potassium chloride - 0.3g/l, Sodium chloride - 6g/l		Injectable solution	236,731 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	148,566 L.L
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	176,974 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 10%	10%	Injectable solution	4,129,004 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 10%	10%	Injectable solution	5,779,226 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 20%	20%	Injectable solution	5,675,800 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 20%	20%	Injectable solution	784,890 L.L
B05XA05	SULFATE DE MAGNESIUM PROAMP	G	Magnesium sulfate - 0.15g/ml	0.15g/ml	Injectable solution	1,400,284 L.L
B05BB01	SERUFLEX LACTATED RINGER'S INJECTION, USP	G	Sodium lactate - 3.1g/l, Calcium chloride, 2H2O - 0.2g/l, Potassium chloride - 0.3g/l, Sodium chloride - 6g/l		Injectable solution	216,046 L.L
B05XA05	SULFATE DE MAGNESIUM RENAUDIN	G	Magnesium sulfate - 1.5g/10ml	15%	Injectable solution	434,061 L.L
B05BB01	SERUFLEX LACTATED RINGER'S INJECTION, USP	G	Sodium lactate - 3.1g/l, Calcium chloride, 2H2O - 0.2g/l, Potassium chloride - 0.3g/l, Sodium chloride - 6g/l		Injectable solution	232,134 L.L
B05BB01	SOLUFLEX LACTATED RINGER'S INJECTION, USP	G	Sodium lactate - 3.1g/l, Calcium chloride, 2H2O - 0.2g/l, Potassium chloride - 0.3g/l, Sodium chloride - 6g/l		Injectable solution	264,311 L.L
L04AB06	SIMPONI	BioTech	Golimumab - 50mg/0.5ml	50mg/0.5ml	Injectable solution	75,598,955 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	L.L
L04AB06	SIMPONI	BioTech	Golimumab - 100mg/1ml	100mg/1ml	Injectable solution	75,598,955 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 45mg	45mg	Injectable solution	157,788,141 L.L

...